초록 ▼

An immunoassay for diagnosing and monitoring human breast cancer. The assay employs a monoclonal antibody which recognizes a human mammary tumor virus derived from the T47D clone-10 breast cancer cell line (HMTV). The monoclonal antibody is produced by the hybridoma cell line deposited with the Amer

An immunoassay for diagnosing and monitoring human breast cancer. The assay employs a monoclonal antibody which recognizes a human mammary tumor virus derived from the T47D clone-10 breast cancer cell line (HMTV). The monoclonal antibody is produced by the hybridoma cell line deposited with the American Type Culture Collection under ATCC Accession No. HB 8630. When the immunoassay is performed on a tissue sample from a subject, the sample is contacted with monoclonal antibody ATCC Accession No. HB 8630 so as to form an antibody-antigen complex between the monoclonal antibody and any HMTV antigens which may be present in the sample. This antibody-antigen complex is then detected employing a second detectable antibody specific to the first monoclonal antibody. The presence or absence of the complex indicates the presence or absence of breast cancer in the subject. When the immunoassay is performed on a body fluid sample from a subject, the sample is first contacted with a detectable soluble antibody so as to form an antibody-antigen complex between the antibody and any HMTV antigens which may be present in the sample. The fluid sample is then contacted by a second antibody which is attached to a solid support. Either the first or second antibody is the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB 8630. The presence or absence of the complex indicates the presence or absence of human breast cancer in the subject.

대표청구항 ▼

An immunoassay for diagnosing and monitoring human breast cancer, wherein said immunoassay is characterized by the use of monoclonal antibodies having a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross

An immunoassay for diagnosing and monitoring human breast cancer, wherein said immunoassay is characterized by the use of monoclonal antibodies having a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross reactions with malignancies of non-breast origin, comprising: contacting a sample with first and second antibodies to form an antibody-antigen complex with any human mammary tumor virus contained in said sample, one of said first and second antibodies being detectable and the other being the monoclonal antibody produced and secreted by hybridoma cell line ATCC Accession determining the presence or absence of detectable antibody in said antibody-antigen complex.